Skip to main content

REVIEW article

Front. Endocrinol.
Sec. Pediatric Endocrinology
Volume 15 - 2024 | doi: 10.3389/fendo.2024.1464803
This article is part of the Research Topic 46,XX Differences of Sex Development (DSD) outside Congenital Adrenal Hyperplasia (CAH) View all 6 articles

Primary Ovarian Insufficiency: update on clinical and genetic findings

Provisionally accepted
  • 1 University of Milan, Milan, Lombardy, Italy
  • 2 Dept of Endocrine and Metabolic Diseases, Italian Auxological Institute (IRCCS), Milan, Italy

The final, formatted version of the article will be published soon.

    Primary ovarian insufficiency (POI) is a disorder of insufficient ovarian follicle function before the age of 40 years with an estimated prevalence of 3.7% worldwide. Its relevance is emerging due to the increasing number of women desiring conception late or beyond the third decade of their lives. POI clinical presentation is extremely heterogeneous with a possible exordium as primary amenorrhea due to ovarian dysgenesis or with a secondary amenorrhea due to different congenital or acquired abnormalities. POI significantly impacts non only on the fertility prospect of the affected women but also on their general, psychological, sexual quality of life, and, furthermore, on their long-term bone, cardiovascular, and cognitive health. In several cases the underlying cause of POI remains unknown and, thus, these forms are still classified as idiopathic. However, we now know the age of menopause is an inheritable trait and POI has a strong genetic background. This is confirmed by the existence of several candidate genes, experimental and natural models. The most common genetic contributors to POI are the X chromosome-linked defects. Moreover, the variable expressivity of POI defect suggests it can be considered as a multifactorial or oligogenic defect. Here, we present an updated review on clinical findings and on the principal X-linked and autosomal genes involved in syndromic and non-syndromic forms of POI. We also provide current information on the management of the premature hypoestrogenic state as well as on fertility preservation in subjects at risk of POI.

    Keywords: Female Hypogonadism, Estradiol, Estradiol replacement therapy, Premature menopause, premature ovarian failure

    Received: 15 Jul 2024; Accepted: 02 Sep 2024.

    Copyright: © 2024 Federici, Rossetti, Moleri, Munari, Frixou, Bonomi and Persani. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Luca Persani, Dept of Endocrine and Metabolic Diseases, Italian Auxological Institute (IRCCS), Milan, 20145, Italy

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.